BioPharmSignal logoBioPharmSignal

Biotech News

Lisata Therapeutics to Present at LD Micro Main Event XIX

Lisata Therapeutics (LSTA)Lisata TherapeuticsCompany update

BASKING RIDGE, N.J. (October 13, 2025) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J.

Related news

LSTALisata Therapeutics2026-08-04 11:00 EST

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

LSTALisata Therapeutics2026-06-10 12:00 EST

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

View all latest news

Lisata Therapeutics

Lisata Therapeutics is a precision oncology company focused on therapies designed to improve tumor penetration and enhance drug delivery into solid tumors. Its story is built around the idea that better access to tumors can improve the performance of other anti-cancer approaches.

Recent company news

LSTALisata Therapeutics2026-08-04 11:00 EST

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

LSTALisata Therapeutics2026-06-10 12:00 EST

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

LSTALisata Therapeutics2026-03-06 23:15 EST

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

LSTALisata Therapeutics2026-01-27 13:00 EST

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

LSTALisata Therapeutics2026-01-21 12:00 EST

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Stock data

Close
1.55 USD
Market cap
31.69M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States